content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Intrexon Corporation (XON)

13.50
-0.11
(-0.81%)
Sep 11, 4:00PM EDT
content_middle

Intrexon Corporation (XON) operates in the synthetic biology field.

XON through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components.

XON’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology.

XON has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; Arch Pharmalabs Ltd.; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005.

Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Previous Close: 
19.85
Open: 
20.07
Bid: 
19.20
Ask: 
20.25
1yr Target Price: 
38.50
Day's Range: 
19.64 - 20.25
52wk Range: 
10.26 - 20.16
Volume: 
612637
Average Daily Volume: 
884570
Market Capitalization: 
1,849.39M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
136.99M
content_right

Pages